Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Nest.Bio Ventures

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 16
Average round size
info
The average size of a deal this fund participated in
$19M
Portfolio companies 10
Rounds per year 2.00
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.38
Exits 1
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity
Seed

Areas of investment

  • Biotechnology
  • Therapeutics
  • Health Care
  • Artificial Intelligence
  • Biopharma
Summary

Nest.Bio Ventures is the famous VC, which was founded in 2016. The fund was located in North America if to be more exact in United States. The main department of described VC is located in the Boston.

The typical startup value when the investment from Nest.Bio Ventures is 100-500 millions dollars. The fund is constantly included in 2-6 deals per year. The high activity for fund was in 2018. The usual things for fund are deals in the range of 10 - 50 millions dollars. This Nest.Bio Ventures works on 18 percentage points less the average amount of lead investments comparing to the other organizations.

Besides them, we counted 4 critical employees of this fund in our database.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Nest.Bio Ventures, startups are often financed by Vivo Capital, Viventures, U.S. Department of Defense. The meaningful sponsors for the fund in investment in the same round are Viventures, Sequoia Capital China, Qiming Venture Partners. In the next rounds fund is usually obtained by Sequoia Capital China, Legend Star, LYFE Capital.

Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Senti Biosciences, HiFiBiO, RootPath Genomics. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in some founders of portfolio startups. When startup sums 1 of the founder, the probability for it to get the investment is little. We can highlight the next thriving fund investment areas, such as Medical, Biopharma.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Nest.Bio Ventures:
Typical Co-investors
Nest.Bio Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Nest.Bio Ventures:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Able Partners New York, New York, United States
Argosy Capital Pennsylvania, United States, Wayne
Authentic Ventures California, Oakland, United States
Corsa Ventures Austin, Texas, United States
Crescendo Venture Partners Israel, Tel Aviv, Tel Aviv
Divine Capital Markets New York, New York, United States
Krungsri Finnovate Bangkok, Krung Thep, Thailand
Lanhua Tengge Touzi -
LG Innovation Ventures California, San Jose, United States
Manchester Technology Fund England, Manchester, United Kingdom
NYC Media Lab Brooklyn, New York, United States
Pros Partners China, Shanghai
RONAholdings California, San Francisco, United States
Ruichuang Touzi China, Shanghai
Semiconductor Manufacturing International China, Shanghai
Shanhua Touzi China, Guangdong, Guangzhou
The Lawrence J. Ellison Revocable Trust California, United States, Walnut Creek
The Pyle Group Madison, United States, Wisconsin
Yangzi Xinrui -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

DeepVerse

Artificial Intelligence
Information Technology
Software
$1M14 Mar 2023 Shanghai, Shanghai, China

PAQ Therapeutics

Biotechnology
Health Care
Therapeutics
$30M15 Jul 2021 Cambridge, Massachusetts, United States

Engine Biosciences

Artificial Intelligence
Biotechnology
Health Care
Machine Learning
$43M26 May 2021 San Francisco, California, United States

RootPath Genomics

Biotechnology
$11M05 Jan 2020 Cambridge, Massachusetts, United States

Platelet BioGenesis

Biotechnology
Ediscovery
Life Science
$26M09 Sep 2019 Newton, Massachusetts, United States

RootPath Genomics

Biotechnology
$7M30 Aug 2018 Cambridge, Massachusetts, United States

POINTS Technology

Artificial Intelligence
Blockchain
Financial Services
FinTech
Service Industry
$8M20 Jul 2018 Singapore, Central, Singapore

Astrocyte Pharmaceuticals

Biotechnology
Clinical Trials
Pharmaceutical
Therapeutics
$2M06 Jun 2018 Cambridge, Massachusetts, United States

HiFiBiO

Biopharma
Biotechnology
Pharmaceutical
Therapeutics
$37M16 May 2018 Ile-de-France
News
PAQ Therapeutics Raises $30M in Series A Funding

– PAQ Therapeutics is a biotechnology company advancing a new approach to restoring health and curing disease through autophagy.
– The company announced the closing of a $30m Series A round.
Sherpa Healthcare Partners led the round with participation from Huagai Capital, MSA Capital, and MRL Ventures Fund as well as seed investors Nest.Bio Ventures and Matrix Partners China.
– The funding will be used to advance the company’s ATTEC platform and progress its pipeline programs.

Engine Biosciences Announces $43 Million Series A Round to Decipher Genetic Codes for New Medicines Through Machine Learning and Next-Generation Combinatorial Genetics

– Engine Biosciences announced the successful completion of an oversubscribed $43m Series A funding round.
– Engine identifies errors in the complex genetic codes of diseases, fixing them with precise therapeutic solutions.
– This round was led by Polaris Partners and also included new investors Invus and one of the world’s premier institutional investors, based in Singapore.
– Existing investors also participated in the Series A, which included 6 Dimensions Capital, WuXi AppTec, DHVC, EDBI, Baidu Ventures, Vectr Ventures, Goodman Capital, WI Harper, and Nest.Bio.
– Amy Schulman, Managing Partner at Polaris Partners, has joined the Engine Biosciences Board of Directors.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Nest.Bio Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 16
Average round size 19M
Rounds per year 2.00
Peak activity year 2018
Lead investments 0
Follow on index 0.38
Exits 1
Group Appearance index 0.08

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

DeepVerse

Artificial Intelligence
Information Technology
Software
$1M14 Mar 2023 Shanghai, Shanghai, China

PAQ Therapeutics

Biotechnology
Health Care
Therapeutics
$30M15 Jul 2021 Cambridge, Massachusetts, United States

Engine Biosciences

Artificial Intelligence
Biotechnology
Health Care
Machine Learning
$43M26 May 2021 San Francisco, California, United States

RootPath Genomics

Biotechnology
$11M05 Jan 2020 Cambridge, Massachusetts, United States

Platelet BioGenesis

Biotechnology
Ediscovery
Life Science
$26M09 Sep 2019 Newton, Massachusetts, United States

RootPath Genomics

Biotechnology
$7M30 Aug 2018 Cambridge, Massachusetts, United States

POINTS Technology

Artificial Intelligence
Blockchain
Financial Services
FinTech
Service Industry
$8M20 Jul 2018 Singapore, Central, Singapore

Astrocyte Pharmaceuticals

Biotechnology
Clinical Trials
Pharmaceutical
Therapeutics
$2M06 Jun 2018 Cambridge, Massachusetts, United States

HiFiBiO

Biopharma
Biotechnology
Pharmaceutical
Therapeutics
$37M16 May 2018 Ile-de-France
Crunchbase icon

Content report

The following text will be sent to our editors: